ARID1A deficiency would compromise the mismatch repair pathway and increase the number of tumor-infiltrating lymphocytes, tumor mutation burden, and expression of PD-L1 in a subset of malignancies, suggesting that ICB treatment would be more effective in these cases (49). The gene discussed is ARID1A; the disease is neoplasm.